NR4A3_MOUSE
ID NR4A3_MOUSE Reviewed; 627 AA.
AC Q9QZB6; Q9QZB5;
DT 26-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT 01-MAY-2000, sequence version 1.
DT 03-AUG-2022, entry version 162.
DE RecName: Full=Nuclear receptor subfamily 4 group A member 3;
DE AltName: Full=Orphan nuclear receptor TEC;
DE AltName: Full=Translocated in extraskeletal chondrosarcoma;
GN Name=Nr4a3; Synonyms=Tec;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC Murinae; Mus; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX PubMed=10701778; DOI=10.1089/104454900314636;
RA Maltais A., Labelle Y.;
RT "Structure and expression of the mouse gene encoding the orphan nuclear
RT receptor TEC.";
RL DNA Cell Biol. 19:121-130(2000).
RN [2]
RP FUNCTION, DISRUPTION PHENOTYPE, AND DEVELOPMENTAL STAGE.
RX PubMed=11784868; DOI=10.1128/mcb.22.3.935-945.2002;
RA Ponnio T., Burton Q., Pereira F.A., Wu D.K., Conneely O.M.;
RT "The nuclear receptor Nor-1 is essential for proliferation of the
RT semicircular canals of the mouse inner ear.";
RL Mol. Cell. Biol. 22:935-945(2002).
RN [3]
RP FUNCTION, REGION, DOMAIN, AND INTERACTION WITH NCOA1; NCOA2; NCOA3; KAT2B;
RP MED1 AND EP300.
RX PubMed=12709428; DOI=10.1074/jbc.m300088200;
RA Wansa K.D., Harris J.M., Yan G., Ordentlich P., Muscat G.E.;
RT "The AF-1 domain of the orphan nuclear receptor NOR-1 mediates trans-
RT activation, coactivator recruitment, and activation by the purine anti-
RT metabolite 6-mercaptopurine.";
RL J. Biol. Chem. 278:24776-24790(2003).
RN [4]
RP FUNCTION, DEVELOPMENTAL STAGE, AND DISRUPTION PHENOTYPE.
RX PubMed=13129926; DOI=10.1074/jbc.m307496200;
RA DeYoung R.A., Baker J.C., Cado D., Winoto A.;
RT "The orphan steroid receptor Nur77 family member Nor-1 is essential for
RT early mouse embryogenesis.";
RL J. Biol. Chem. 278:47104-47109(2003).
RN [5]
RP FUNCTION, DISRUPTION PHENOTYPE, AND DEVELOPMENTAL STAGE.
RX PubMed=15456880; DOI=10.1128/mcb.24.20.9070-9078.2004;
RA Ponnio T., Conneely O.M.;
RT "nor-1 regulates hippocampal axon guidance, pyramidal cell survival, and
RT seizure susceptibility.";
RL Mol. Cell. Biol. 24:9070-9078(2004).
RN [6]
RP FUNCTION.
RX PubMed=18325999; DOI=10.1210/en.2007-1202;
RA Pearen M.A., Myers S.A., Raichur S., Ryall J.G., Lynch G.S., Muscat G.E.;
RT "The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling,
RT regulates gene expression that controls oxidative metabolism in skeletal
RT muscle.";
RL Endocrinology 149:2853-2865(2008).
RN [7]
RP FUNCTION.
RX PubMed=18945812; DOI=10.1210/me.2008-0161;
RA Chao L.C., Bensinger S.J., Villanueva C.J., Wroblewski K., Tontonoz P.;
RT "Inhibition of adipocyte differentiation by Nur77, Nurr1, and Nor1.";
RL Mol. Endocrinol. 22:2596-2608(2008).
RN [8]
RP FUNCTION.
RX PubMed=19523439; DOI=10.1016/j.bbrc.2009.06.023;
RA Nonogaki K., Kaji T., Ohba Y., Sumii M., Wakameda M., Tamari T.;
RT "Serotonin 5-HT2C receptor-independent expression of hypothalamic NOR1, a
RT novel modulator of food intake and energy balance, in mice.";
RL Biochem. Biophys. Res. Commun. 386:311-315(2009).
RN [9]
RP FUNCTION.
RX PubMed=19153266; DOI=10.1161/circulationaha.108.822056;
RA Nomiyama T., Zhao Y., Gizard F., Findeisen H.M., Heywood E.B., Jones K.L.,
RA Conneely O.M., Bruemmer D.;
RT "Deficiency of the NR4A neuron-derived orphan receptor-1 attenuates
RT neointima formation after vascular injury.";
RL Circulation 119:577-586(2009).
RN [10]
RP FUNCTION, AND INDUCTION.
RX PubMed=20558821; DOI=10.1161/circresaha.110.222083;
RA Zhao Y., Howatt D.A., Gizard F., Nomiyama T., Findeisen H.M., Heywood E.B.,
RA Jones K.L., Conneely O.M., Daugherty A., Bruemmer D.;
RT "Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte
RT adhesion and atherosclerosis.";
RL Circ. Res. 107:501-511(2010).
RN [11]
RP FUNCTION.
RX PubMed=20566846; DOI=10.1073/pnas.1007088107;
RA Volakakis N., Kadkhodaei B., Joodmardi E., Wallis K., Panman L.,
RA Silvaggi J., Spiegelman B.M., Perlmann T.;
RT "NR4A orphan nuclear receptors as mediators of CREB-dependent
RT neuroprotection.";
RL Proc. Natl. Acad. Sci. U.S.A. 107:12317-12322(2010).
RN [12]
RP FUNCTION.
RX PubMed=21868379; DOI=10.1074/jbc.m111.295840;
RA Gizard F., Zhao Y., Findeisen H.M., Qing H., Cohn D., Heywood E.B.,
RA Jones K.L., Nomiyama T., Bruemmer D.;
RT "Transcriptional regulation of S phase kinase-associated protein 2 by NR4A
RT orphan nuclear receptor NOR1 in vascular smooth muscle cells.";
RL J. Biol. Chem. 286:35485-35493(2011).
RN [13]
RP FUNCTION, INDUCTION, TISSUE SPECIFICITY, AND DISRUPTION PHENOTYPE.
RX PubMed=23897430; DOI=10.1128/mcb.00385-13;
RA Kim S.G., Lee B., Kim D.H., Kim J., Lee S., Lee S.K., Lee J.W.;
RT "Control of energy balance by hypothalamic gene circuitry involving two
RT nuclear receptors, neuron-derived orphan receptor 1 and glucocorticoid
RT receptor.";
RL Mol. Cell. Biol. 33:3826-3834(2013).
RN [14]
RP FUNCTION.
RX PubMed=24586680; DOI=10.1371/journal.pone.0089311;
RA Garcia-Faroldi G., Melo F.R., Bruemmer D., Conneely O.M., Pejler G.,
RA Lundequist A.;
RT "Nuclear receptor 4a3 (nr4a3) regulates murine mast cell responses and
RT granule content.";
RL PLoS ONE 9:E89311-E89311(2014).
RN [15]
RP FUNCTION.
RX PubMed=24806827; DOI=10.1002/stem.1747;
RA Qing H., Liu Y., Zhao Y., Aono J., Jones K.L., Heywood E.B., Howatt D.,
RA Binkley C.M., Daugherty A., Liang Y., Bruemmer D.;
RT "Deficiency of the NR4A orphan nuclear receptor NOR1 in hematopoietic stem
RT cells accelerates atherosclerosis.";
RL Stem Cells 32:2419-2429(2014).
CC -!- FUNCTION: Transcriptional activator that binds to regulatory elements
CC in promoter regions in a cell- and response element (target)-specific
CC manner (PubMed:12709428). Induces gene expression by binding as
CC monomers to the NR4A1 response element (NBRE) 5'-AAAAGGTCA-3' site and
CC as homodimers to the Nur response element (NurRE) site in the promoter
CC of their regulated target genes (By similarity). Plays a role in the
CC regulation of proliferation, survival and differentiation of many
CC different cell types and also in metabolism and inflammation. Mediates
CC proliferation of vascular smooth muscle, myeloid progenitor cell and
CC type B pancreatic cells; promotes mitogen-induced vascular smooth
CC muscle cell proliferation through transactivation of SKP2 promoter by
CC binding a NBRE site (PubMed:21868379). Upon PDGF stimulation,
CC stimulates vascular smooth muscle cell proliferation by regulating
CC CCND1 and CCND2 expression. In islets, induces type B pancreatic cell
CC proliferation through up-regulation of genes that activate cell cycle,
CC as well as genes that cause degradation of the CDKN1A (By similarity).
CC Negatively regulates myeloid progenitor cell proliferation by
CC repressing RUNX1 in a NBRE site-independent manner (PubMed:24806827).
CC During inner ear, plays a role as a key mediator of the proliferative
CC growth phase of semicircular canal development (PubMed:11784868).
CC Mediates also survival of neuron and smooth muscle cells; mediates
CC CREB-induced neuronal survival, and during hippocampus development,
CC plays a critical role in pyramidal cell survival and axonal guidance
CC (PubMed:20566846, PubMed:15456880). Is required for S phase entry of
CC the cell cycle and survival of smooth muscle cells by inducing CCND1,
CC resulting in RB1 phosphorylation. Binds to NBRE motif in CCND1
CC promoter, resulting in the activation of the promoter and CCND1
CC transcription (PubMed:19153266). Also plays a role in inflammation;
CC upon TNF stimulation, mediates monocyte adhesion by inducing the
CC expression of VCAM1 and ICAM1 by binding to the NBRE consensus site
CC (PubMed:20558821). In mast cells activated by Fc-epsilon receptor
CC cross-linking, promotes the synthesis and release of cytokines but
CC impairs events leading to degranulation (PubMed:24586680). Also plays a
CC role in metabolism; by modulating feeding behavior; and by playing a
CC role in energy balance by inhibiting the glucocorticoid-induced
CC orexigenic neuropeptides AGRP expression, at least in part by forming a
CC complex with activated NR3C1 on the AGRP- glucocorticoid response
CC element (GRE), and thus weakening the DNA binding activity of NR3C1
CC (PubMed:23897430, PubMed:19523439). Upon catecholamines stimulation,
CC regulates gene expression that controls oxidative metabolism in
CC skeletal muscle (PubMed:18325999). Plays a role in glucose transport by
CC regulating translocation of the SLC2A4 glucose transporter to the cell
CC surface (By similarity). Finally, during gastrulation plays a crucial
CC role in the formation of anterior mesoderm by controlling cell
CC migration (PubMed:13129926). Inhibits adipogenesis (PubMed:18945812).
CC Also participates in cardiac hypertrophy by activating PARP1 (By
CC similarity). {ECO:0000250|UniProtKB:P51179,
CC ECO:0000250|UniProtKB:Q92570, ECO:0000269|PubMed:11784868,
CC ECO:0000269|PubMed:12709428, ECO:0000269|PubMed:13129926,
CC ECO:0000269|PubMed:15456880, ECO:0000269|PubMed:18325999,
CC ECO:0000269|PubMed:18945812, ECO:0000269|PubMed:19153266,
CC ECO:0000269|PubMed:19523439, ECO:0000269|PubMed:20558821,
CC ECO:0000269|PubMed:20566846, ECO:0000269|PubMed:21868379,
CC ECO:0000269|PubMed:23897430, ECO:0000269|PubMed:24586680,
CC ECO:0000269|PubMed:24806827}.
CC -!- SUBUNIT: Interacts with SIX3 (via homeobox); differentially regulates
CC the transcriptional activities of NR4A3. Interacts with NCOA2;
CC potentiates the activity of the NR4A3 (PubMed:12709428). Interacts with
CC NCOA1, NCOA3, MED1 and KAT2B. Interacts with EP300 and NCOA2; mediates
CC the recruitment of MED1 in the coactivator complex (PubMed:12709428).
CC Interacts with the constituents of DNA-PK heterotrimer PRKDC, XRCC6 and
CC XRCC5; phosphorylates and prevents NR4A3 ubiquitinylation and
CC degradation (By similarity). Interacts with NR3C1 (via nuclear receptor
CC DNA-binding domain); the interactions represses transcription activity
CC of NR4A3 on the POMC promoter Nur response element (NurRE). Interacts
CC with TRIM28; the interactions potentiates NR4A3 activity on NurRE
CC promoter. Binds DNA as a monomer and homodimer. Interacts with PARP1;
CC activates PARP1 by improving acetylation of PARP1 and suppressing the
CC interaction between PARP1 and SIRT1 (By similarity).
CC {ECO:0000250|UniProtKB:P51179, ECO:0000250|UniProtKB:Q92570,
CC ECO:0000269|PubMed:12709428}.
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00407}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1; Synonyms=Long;
CC IsoId=Q9QZB6-1; Sequence=Displayed;
CC Name=2; Synonyms=Short, TECdeltaC;
CC IsoId=Q9QZB6-2; Sequence=VSP_010083, VSP_010084;
CC -!- TISSUE SPECIFICITY: Ubiquitous. Highest levels of expression in brain.
CC Widely expressed throughout the arcuate nucleus region of the
CC hypothalamus, namely in AgRP neurons.
CC -!- DEVELOPMENTAL STAGE: Not expressed during the earliest stages of
CC vesicle formation (10.5 dpc). Expression begins coincidentally with the
CC initiation of regional shape changes in the otic vesicle at 11.5 dpc
CC and is restricted to the dorsolateral region. At 13.5 dpc, expression
CC is limited to the inner edge of the semicircular canal epithelium,
CC flanking the site of fusion, and this restricted expression continues
CC at P1 (PubMed:11784868). At 14.5 dpc expression is observed in the
CC primitive plexiform layer of the hippocampus. At P0, expression is
CC observed in both the pyramidal and granule cell layers. Expression
CC persistes in these cells in the adult hippocampus after their postnatal
CC maturation. In addition, expression is also observed in the hilar mossy
CC cells of the dentate gyrus (PubMed:15456880). At 7.5 dpc expression is
CC ubiquitous, whereas at 9 dpc and 9.5 dpc, expression is restricted to
CC the brain (PubMed:13129926). {ECO:0000269|PubMed:11784868,
CC ECO:0000269|PubMed:13129926, ECO:0000269|PubMed:15456880}.
CC -!- INDUCTION: Induced by inflammatory stimuli (PubMed:20558821). Up-
CC regulated by the anorexigenic signal leptin via the transcription
CC factor cyclic AMP response element-binding protein (CREB). Suppressed
CC by orexigenic signal glucocorticoid that mobilizes NR3C1 to inhibit
CC NR4A3 expression by antagonizing the action of CREB (PubMed:23897430).
CC {ECO:0000269|PubMed:20558821, ECO:0000269|PubMed:23897430}.
CC -!- DOMAIN: The AF-1 domain mediates transcription activation. The N-
CC terminal region (1-292) directly interacts with the C-terminal LBD
CC (380-627): the interaction is potentiated by AF-1-mediated recruitment
CC of NCOA2. {ECO:0000269|PubMed:12709428}.
CC -!- PTM: Phosphorylated by PRKDC. {ECO:0000250|UniProtKB:Q92570}.
CC -!- DISRUPTION PHENOTYPE: Nr4a3 homozygous knockout mice are viable and
CC normal in appearance; however, abnormal hyperactive and partial
CC bidirectional circling behavior is observed by 3 weeks of age in 15% of
CC these mice. The circling behavior is interspersed with noncircling
CC periods of feeding, grooming, and sleep (PubMed:11784868). A small
CC percentage of adult Nr4a3 homozygotes displayes brief freezing spells
CC with tonic posturing that are exacerbated with handling
CC (PubMed:15456880). The overall food consumption of Nr4a3 homozygous
CC knockout mice is higher. Moreover, Nr4a3 homozygous mice lose more body
CC weight upon fasting but clearly consumed more food during refeeding. By
CC the end of the fasting period, Nr4a3 homozygous mice display signs of
CC exhaustion (PubMed:23897430). Nr4a3 homozygous leads to embryonic
CC lethality around 8.5 dpc (PubMed:13129926).
CC {ECO:0000269|PubMed:11784868, ECO:0000269|PubMed:13129926,
CC ECO:0000269|PubMed:15456880, ECO:0000269|PubMed:23897430}.
CC -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR4
CC subfamily. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AF191211; AAF05622.1; -; mRNA.
DR EMBL; AF191212; AAF05623.1; -; mRNA.
DR CCDS; CCDS18163.1; -. [Q9QZB6-1]
DR RefSeq; NP_001294918.1; NM_001307989.1. [Q9QZB6-2]
DR RefSeq; NP_056558.1; NM_015743.3. [Q9QZB6-1]
DR RefSeq; XP_006537719.1; XM_006537656.3. [Q9QZB6-1]
DR RefSeq; XP_006537720.1; XM_006537657.3. [Q9QZB6-1]
DR RefSeq; XP_006537721.1; XM_006537658.1. [Q9QZB6-1]
DR AlphaFoldDB; Q9QZB6; -.
DR SMR; Q9QZB6; -.
DR BioGRID; 201804; 21.
DR IntAct; Q9QZB6; 3.
DR STRING; 10090.ENSMUSP00000030025; -.
DR PhosphoSitePlus; Q9QZB6; -.
DR MaxQB; Q9QZB6; -.
DR PaxDb; Q9QZB6; -.
DR PRIDE; Q9QZB6; -.
DR ProteomicsDB; 293722; -. [Q9QZB6-1]
DR ProteomicsDB; 293723; -. [Q9QZB6-2]
DR Antibodypedia; 29057; 424 antibodies from 31 providers.
DR DNASU; 18124; -.
DR Ensembl; ENSMUST00000030025; ENSMUSP00000030025; ENSMUSG00000028341. [Q9QZB6-1]
DR GeneID; 18124; -.
DR KEGG; mmu:18124; -.
DR UCSC; uc008suu.1; mouse. [Q9QZB6-1]
DR UCSC; uc008suv.1; mouse. [Q9QZB6-2]
DR CTD; 8013; -.
DR MGI; MGI:1352457; Nr4a3.
DR VEuPathDB; HostDB:ENSMUSG00000028341; -.
DR eggNOG; KOG4217; Eukaryota.
DR GeneTree; ENSGT00950000183038; -.
DR HOGENOM; CLU_007368_14_2_1; -.
DR InParanoid; Q9QZB6; -.
DR OrthoDB; 454476at2759; -.
DR PhylomeDB; Q9QZB6; -.
DR TreeFam; TF315430; -.
DR Reactome; R-MMU-383280; Nuclear Receptor transcription pathway.
DR BioGRID-ORCS; 18124; 4 hits in 76 CRISPR screens.
DR ChiTaRS; Nr4a3; mouse.
DR PRO; PR:Q9QZB6; -.
DR Proteomes; UP000000589; Chromosome 4.
DR RNAct; Q9QZB6; protein.
DR Bgee; ENSMUSG00000028341; Expressed in CA1 field of hippocampus and 151 other tissues.
DR ExpressionAtlas; Q9QZB6; baseline and differential.
DR Genevisible; Q9QZB6; MM.
DR GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR GO; GO:0005667; C:transcription regulator complex; IDA:MGI.
DR GO; GO:0035497; F:cAMP response element binding; IDA:UniProtKB.
DR GO; GO:0003677; F:DNA binding; ISO:MGI.
DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:UniProtKB.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR GO; GO:0035259; F:nuclear glucocorticoid receptor binding; ISO:MGI.
DR GO; GO:0004879; F:nuclear receptor activity; IEA:InterPro.
DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR GO; GO:0019901; F:protein kinase binding; ISO:MGI.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:MGI.
DR GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB.
DR GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR GO; GO:0030534; P:adult behavior; IMP:MGI.
DR GO; GO:0007411; P:axon guidance; IMP:MGI.
DR GO; GO:0045333; P:cellular respiration; IMP:UniProtKB.
DR GO; GO:0071870; P:cellular response to catecholamine stimulus; IDA:UniProtKB.
DR GO; GO:0071376; P:cellular response to corticotropin-releasing hormone stimulus; IDA:UniProtKB.
DR GO; GO:0044320; P:cellular response to leptin stimulus; IDA:UniProtKB.
DR GO; GO:0035726; P:common myeloid progenitor cell proliferation; IMP:UniProtKB.
DR GO; GO:0097048; P:dendritic cell apoptotic process; IMP:MGI.
DR GO; GO:0097009; P:energy homeostasis; IMP:UniProtKB.
DR GO; GO:0045444; P:fat cell differentiation; IDA:UniProtKB.
DR GO; GO:0007369; P:gastrulation; IMP:UniProtKB.
DR GO; GO:0021766; P:hippocampus development; IMP:MGI.
DR GO; GO:0042472; P:inner ear morphogenesis; IMP:MGI.
DR GO; GO:0043303; P:mast cell degranulation; IMP:UniProtKB.
DR GO; GO:0001707; P:mesoderm formation; IMP:MGI.
DR GO; GO:1903208; P:negative regulation of hydrogen peroxide-induced neuron death; IMP:UniProtKB.
DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:MGI.
DR GO; GO:1903204; P:negative regulation of oxidative stress-induced neuron death; IGI:UniProtKB.
DR GO; GO:0034392; P:negative regulation of smooth muscle cell apoptotic process; IMP:MGI.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR GO; GO:0050885; P:neuromuscular process controlling balance; IMP:MGI.
DR GO; GO:0051402; P:neuron apoptotic process; IMP:MGI.
DR GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; ISO:MGI.
DR GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB.
DR GO; GO:0045787; P:positive regulation of cell cycle; IMP:MGI.
DR GO; GO:2000670; P:positive regulation of dendritic cell apoptotic process; IMP:MGI.
DR GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:UniProtKB.
DR GO; GO:0046321; P:positive regulation of fatty acid oxidation; IMP:UniProtKB.
DR GO; GO:2000253; P:positive regulation of feeding behavior; IMP:UniProtKB.
DR GO; GO:0010828; P:positive regulation of glucose transmembrane transport; ISS:UniProtKB.
DR GO; GO:0038097; P:positive regulation of mast cell activation by Fc-epsilon receptor signaling pathway; IMP:UniProtKB.
DR GO; GO:0032765; P:positive regulation of mast cell cytokine production; IMP:UniProtKB.
DR GO; GO:1900625; P:positive regulation of monocyte aggregation; IMP:UniProtKB.
DR GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:UniProtKB.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; ISO:MGI.
DR GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; ISO:MGI.
DR GO; GO:0009444; P:pyruvate oxidation; IMP:UniProtKB.
DR GO; GO:0048660; P:regulation of smooth muscle cell proliferation; ISS:UniProtKB.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR GO; GO:0061469; P:regulation of type B pancreatic cell proliferation; ISS:UniProtKB.
DR GO; GO:0042542; P:response to hydrogen peroxide; IMP:MGI.
DR GO; GO:0048752; P:semicircular canal morphogenesis; IMP:MGI.
DR GO; GO:0034390; P:smooth muscle cell apoptotic process; IMP:MGI.
DR GO; GO:0060005; P:vestibular reflex; IMP:MGI.
DR Gene3D; 1.10.565.10; -; 1.
DR Gene3D; 3.30.50.10; -; 1.
DR InterPro; IPR035500; NHR-like_dom_sf.
DR InterPro; IPR003072; NOR1_rcpt.
DR InterPro; IPR003070; Nuc_orph_rcpt.
DR InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR InterPro; IPR001628; Znf_hrmn_rcpt.
DR InterPro; IPR013088; Znf_NHR/GATA.
DR Pfam; PF00104; Hormone_recep; 1.
DR Pfam; PF00105; zf-C4; 1.
DR PRINTS; PR01286; NORNUCRECPTR.
DR PRINTS; PR01284; NUCLEARECPTR.
DR PRINTS; PR00398; STRDHORMONER.
DR PRINTS; PR00047; STROIDFINGER.
DR SMART; SM00430; HOLI; 1.
DR SMART; SM00399; ZnF_C4; 1.
DR SUPFAM; SSF48508; SSF48508; 1.
DR PROSITE; PS51843; NR_LBD; 1.
DR PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE 1: Evidence at protein level;
KW Alternative splicing; DNA-binding; Metal-binding; Nucleus; Receptor;
KW Reference proteome; Transcription; Transcription regulation; Zinc;
KW Zinc-finger.
FT CHAIN 1..627
FT /note="Nuclear receptor subfamily 4 group A member 3"
FT /id="PRO_0000053723"
FT DOMAIN 395..624
FT /note="NR LBD"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01189"
FT DNA_BIND 290..365
FT /note="Nuclear receptor"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT ZN_FING 293..313
FT /note="NR C4-type"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT ZN_FING 329..353
FT /note="NR C4-type"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00407"
FT REGION 1..292
FT /note="Interaction with NCOA1, NCOA2, NCOA3 and KAT2B"
FT /evidence="ECO:0000269|PubMed:12709428"
FT REGION 1..139
FT /note="Required for DNA-PK heterotrimer"
FT /evidence="ECO:0000250|UniProtKB:Q92570"
FT REGION 1..112
FT /note="Activation function (AF)-1 domain"
FT /evidence="ECO:0000269|PubMed:12709428"
FT REGION 96..162
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 268..289
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 365..395
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 380..627
FT /note="Interaction with KAT2B"
FT /evidence="ECO:0000269|PubMed:12709428"
FT COMPBIAS 98..113
FT /note="Basic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT VAR_SEQ 420..429
FT /note="YCPTDQATAG -> VSSMNAFEPL (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:10701778"
FT /id="VSP_010083"
FT VAR_SEQ 430..627
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:10701778"
FT /id="VSP_010084"
SQ SEQUENCE 627 AA; 68454 MW; 2F49CB4C8DE315A8 CRC64;
MPCVQAQYSP SPPGSTYATQ TYGSEYTTEI MNPDYTKLTM DLGSTGIMAT ATTSLPSFST
FMEGYPSSCE LKPSCLYQMP PSGPRPLIKM EEGREHGYHH HHHHHHHHHH HQQQQPSIPP
PSGPEDEVLP STSMYFKQSP PSTPTTPGFP PQAGALWDDE LPSAPGCIAP GPLLDPQMKA
VPPMAAAARF PIFFKPSPPH PPAPSPAGGH HLGYDPTAAA ALSLPLGAAA AAGSQAAALE
GHPYGLPLAK RTATLTFPPL GLTASPTASS LLGESPSLPS PPNRSSSSGE GTCAVCGDNA
ACQHYGVRTC EGCKGFFKRT VQKNAKYVCL ANKNCPVDKR RRNRCQYCRF QKCLSVGMVK
EVVRTDSLKG RRGRLPSKPK SPLQQEPSQP SPPSPPICMM NALVRALTDA TPRDLDYSRY
CPTDQATAGT DAEHVQQFYN LLTASIDVSR SWAEKIPGFT DLPKEDQTLL IESAFLELFV
LRLSIRSNTA EDKFVFCNGL VLHRLQCLRG FGEWLDSIKD FSLNLQSLNL DIQALACLSA
LSMITERHGL KEPKRVEELC TKITSSLKDH QRKGQALEPS EPKVLRALVE LRKICTQGLQ
RIFYLKLEDL VPPPSVIDKL FLDTLPF
